Q5131 — Injection, adalimumab-aacf (idacio), biosimilar, 20 mg
Q5131 is a HCPCS Level II code for injection, adalimumab-aacf (idacio), biosimilar, 20 mg. It belongs to the Temporary Codes section. It was terminated on December 31, 2024 and is not valid on new claims.
This code has been terminated
CMS terminated Q5131 on December 31, 2024. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for Q5131
- Long descriptor
- Injection, adalimumab-aacf (idacio), biosimilar, 20 mg
- Short descriptor
- Inj, idacio, 20 mg
- Added
- July 1, 2023
- Terminated
- December 31, 2024
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to Q5131
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If Q5131 is not quite right, the correct code is very often within a few positions of it.
- Q5123Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
- Q5124Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg
- Q5125Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
- Q5126Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
- Q5127Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg
- Q5128Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg
- Q5129Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
- Q5130Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg
- Q5132Injection, adalimumab-afzb (abrilada), biosimilar, 10 mgterminated
- Q5133Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
- Q5134Injection, natalizumab-sztn (tyruko), biosimilar, 1 mg
- Q5135Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg
- Q5136Injection, denosumab-bbdz (jubbonti/wyost), biosimilar, 1 mg
- Q5137Injection, ustekinumab-auub (wezlana), biosimilar, subcutaneous, 1 mg
- Q5138Injection, ustekinumab-auub (wezlana), biosimilar, intravenous, 1 mg
- Q5139Injection, eculizumab-aeeb (bkemv), biosimilar, 10 mgterminated
Questions about Q5131
What is HCPCS code Q5131?
Q5131 is a HCPCS Level II code for injection, adalimumab-aacf (idacio), biosimilar, 20 mg. It sits in the Temporary Codes section.
Does Medicare cover Q5131?
The CMS HCPCS file marks Q5131 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is Q5131 still valid?
No. Q5131 was terminated on December 31, 2024 and should not be used on new claims.